Novo Nordisk has ended a clinical trial evaluating the impact of semaglutide on kidney function after the results from an interim analysis met certain pre-specified criteria, according to a company press release. To protect the integrity of the trial, Novo Nordisk will remain blinded to the results until the trial is completed, likely during the first half of 2024, according to the release. The FLOW trial (Effect of semaglutide vs. placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease), is a randomized, double-blind, parallel-group,